REPEL-CV BIORESORBABLE ADHESION BARRIER

FDA Premarket Approval P070005

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the repel-cv bioresorbable adhesion barrier. The device is indicated for reducing the severity of post-operative cardiac adhesions in pediatric patients who are likely to require reoperation via sternotomy.

DeviceREPEL-CV BIORESORBABLE ADHESION BARRIER
Generic NameBarrier, Adhesion, Cardiovascular
ApplicantPATHFINDER CELL THERAPY INC.
Date Received2007-01-30
Decision Date2009-03-06
Notice Date2009-03-11
PMAP070005
SupplementS
Product CodeOBD 
Docket Number09M-0135
Advisory CommitteeCardiovascular
Expedited ReviewNo
Combination Product No
Applicant Address PATHFINDER CELL THERAPY INC. 12 Bow Street cambridge, MA 02138
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Post-Approval Study:Show Report Schedule and Study Progress
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P070005Original Filing
S002 2011-03-07 Normal 180 Day Track No User Fee
S001

© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.